167 related articles for article (PubMed ID: 22880004)
1. Mouse p53-deficient cancer models as platforms for obtaining genomic predictors of human cancer clinical outcomes.
Dueñas M; Santos M; Aranda JF; Bielza C; Martínez-Cruz AB; Lorz C; Taron M; Ciruelos EM; Rodríguez-Peralto JL; Martín M; Larrañaga P; Dahabreh J; Stathopoulos GP; Rosell R; Paramio JM; García-Escudero R
PLoS One; 2012; 7(8):e42494. PubMed ID: 22880004
[TBL] [Abstract][Full Text] [Related]
2. Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells.
Herschkowitz JI; Zhao W; Zhang M; Usary J; Murrow G; Edwards D; Knezevic J; Greene SB; Darr D; Troester MA; Hilsenbeck SG; Medina D; Perou CM; Rosen JM
Proc Natl Acad Sci U S A; 2012 Feb; 109(8):2778-83. PubMed ID: 21633010
[TBL] [Abstract][Full Text] [Related]
3. Genomic profiling of murine mammary tumors identifies potential personalized drug targets for p53-deficient mammary cancers.
Pfefferle AD; Agrawal YN; Koboldt DC; Kanchi KL; Herschkowitz JI; Mardis ER; Rosen JM; Perou CM
Dis Model Mech; 2016 Jul; 9(7):749-57. PubMed ID: 27149990
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive genomic profiles of small cell lung cancer.
George J; Lim JS; Jang SJ; Cun Y; Ozretić L; Kong G; Leenders F; Lu X; Fernández-Cuesta L; Bosco G; Müller C; Dahmen I; Jahchan NS; Park KS; Yang D; Karnezis AN; Vaka D; Torres A; Wang MS; Korbel JO; Menon R; Chun SM; Kim D; Wilkerson M; Hayes N; Engelmann D; Pützer B; Bos M; Michels S; Vlasic I; Seidel D; Pinther B; Schaub P; Becker C; Altmüller J; Yokota J; Kohno T; Iwakawa R; Tsuta K; Noguchi M; Muley T; Hoffmann H; Schnabel PA; Petersen I; Chen Y; Soltermann A; Tischler V; Choi CM; Kim YH; Massion PP; Zou Y; Jovanovic D; Kontic M; Wright GM; Russell PA; Solomon B; Koch I; Lindner M; Muscarella LA; la Torre A; Field JK; Jakopovic M; Knezevic J; Castaños-Vélez E; Roz L; Pastorino U; Brustugun OT; Lund-Iversen M; Thunnissen E; Köhler J; Schuler M; Botling J; Sandelin M; Sanchez-Cespedes M; Salvesen HB; Achter V; Lang U; Bogus M; Schneider PM; Zander T; Ansén S; Hallek M; Wolf J; Vingron M; Yatabe Y; Travis WD; Nürnberg P; Reinhardt C; Perner S; Heukamp L; Büttner R; Haas SA; Brambilla E; Peifer M; Sage J; Thomas RK
Nature; 2015 Aug; 524(7563):47-53. PubMed ID: 26168399
[TBL] [Abstract][Full Text] [Related]
5. A P53-Deficiency Gene Signature Predicts Recurrence Risk of Patients with Early-Stage Lung Adenocarcinoma.
Zhao Y; Varn FS; Cai G; Xiao F; Amos CI; Cheng C
Cancer Epidemiol Biomarkers Prev; 2018 Jan; 27(1):86-95. PubMed ID: 29141854
[No Abstract] [Full Text] [Related]
6. Lung tumors with distinct p53 mutations respond similarly to p53 targeted therapy but exhibit genotype-specific statin sensitivity.
Turrell FK; Kerr EM; Gao M; Thorpe H; Doherty GJ; Cridge J; Shorthouse D; Speed A; Samarajiwa S; Hall BA; Griffiths M; Martins CP
Genes Dev; 2017 Jul; 31(13):1339-1353. PubMed ID: 28790158
[TBL] [Abstract][Full Text] [Related]
7. Combined Immunohistochemistry of PLK1, p21, and p53 for Predicting TP53 Status: An Independent Prognostic Factor of Breast Cancer.
Watanabe G; Ishida T; Furuta A; Takahashi S; Watanabe M; Nakata H; Kato S; Ishioka C; Ohuchi N
Am J Surg Pathol; 2015 Aug; 39(8):1026-34. PubMed ID: 26171916
[TBL] [Abstract][Full Text] [Related]
8. Knockout and transgenic mice of Trp53: what have we learned about p53 in breast cancer?
Blackburn AC; Jerry DJ
Breast Cancer Res; 2002; 4(3):101-11. PubMed ID: 12052252
[TBL] [Abstract][Full Text] [Related]
9. Airway basal cells of healthy smokers express an embryonic stem cell signature relevant to lung cancer.
Shaykhiev R; Wang R; Zwick RK; Hackett NR; Leung R; Moore MA; Sima CS; Chao IW; Downey RJ; Strulovici-Barel Y; Salit J; Crystal RG
Stem Cells; 2013 Sep; 31(9):1992-2002. PubMed ID: 23857717
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive genomic characterization of squamous cell lung cancers.
Cancer Genome Atlas Research Network
Nature; 2012 Sep; 489(7417):519-25. PubMed ID: 22960745
[TBL] [Abstract][Full Text] [Related]
11. Rad51c- and Trp53-double-mutant mouse model reveals common features of homologous recombination-deficient breast cancers.
Tumiati M; Munne PM; Edgren H; Eldfors S; Hemmes A; Kuznetsov SG
Oncogene; 2016 Sep; 35(35):4601-10. PubMed ID: 26820992
[TBL] [Abstract][Full Text] [Related]
12. miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma.
Kasinski AL; Slack FJ
Cancer Res; 2012 Nov; 72(21):5576-87. PubMed ID: 22964582
[TBL] [Abstract][Full Text] [Related]
13. Gene expression profiling of mouse p53-deficient epidermal carcinoma defines molecular determinants of human cancer malignancy.
García-Escudero R; Martínez-Cruz AB; Santos M; Lorz C; Segrelles C; Garaulet G; Saiz-Ladera C; Costa C; Buitrago-Pérez A; Dueñas M; Paramio JM
Mol Cancer; 2010 Jul; 9():193. PubMed ID: 20630075
[TBL] [Abstract][Full Text] [Related]
14. Predicting clinical outcomes of cancer patients with a p53 deficiency gene signature.
Schaafsma E; Takacs EM; Kaur S; Cheng C; Kurokawa M
Sci Rep; 2022 Jan; 12(1):1317. PubMed ID: 35079034
[TBL] [Abstract][Full Text] [Related]
15. Development and validation of a prognostic gene-expression signature for lung adenocarcinoma.
Park YY; Park ES; Kim SB; Kim SC; Sohn BH; Chu IS; Jeong W; Mills GB; Byers LA; Lee JS
PLoS One; 2012; 7(9):e44225. PubMed ID: 22970185
[TBL] [Abstract][Full Text] [Related]
16. Human cancer-associated mutations in the Aα subunit of protein phosphatase 2A increase lung cancer incidence in Aα knock-in and knockout mice.
Ruediger R; Ruiz J; Walter G
Mol Cell Biol; 2011 Sep; 31(18):3832-44. PubMed ID: 21791616
[TBL] [Abstract][Full Text] [Related]
17. S100a4 upregulation in Pik3caH1047R;Trp53R270H;MMTV-Cre-driven mammary tumors promotes metastasis.
Yuan W; Goldstein LD; Durinck S; Chen YJ; Nguyen TT; Kljavin NM; Sokol ES; Stawiski EW; Haley B; Ziai J; Modrusan Z; Seshagiri S
Breast Cancer Res; 2019 Dec; 21(1):152. PubMed ID: 31881983
[TBL] [Abstract][Full Text] [Related]
18. Association of the germline TP53 R72P and MDM2 SNP309 variants with breast cancer survival in specific breast tumor subgroups.
van den Broek AJ; Broeks A; Horlings HM; Canisius SV; Braaf LM; Langerød A; Van't Veer LJ; Schmidt MK
Breast Cancer Res Treat; 2011 Nov; 130(2):599-608. PubMed ID: 21667122
[TBL] [Abstract][Full Text] [Related]
19. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry.
Sjögren S; Inganäs M; Norberg T; Lindgren A; Nordgren H; Holmberg L; Bergh J
J Natl Cancer Inst; 1996 Feb; 88(3-4):173-82. PubMed ID: 8632491
[TBL] [Abstract][Full Text] [Related]
20. Gene expression profiling of isogenic cells with different TP53 gene dosage reveals numerous genes that are affected by TP53 dosage and identifies CSPG2 as a direct target of p53.
Yoon H; Liyanarachchi S; Wright FA; Davuluri R; Lockman JC; de la Chapelle A; Pellegata NS
Proc Natl Acad Sci U S A; 2002 Nov; 99(24):15632-7. PubMed ID: 12438652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
